EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐ AChR Antibody‐Positive Myasthenia Gravis: FGF ‐19 as a Novel Biomarker

Tiancheng Luo, Deyou Peng, Zhouao Zhang iD, Mingjin Yang, Xinyan Guo, Tianyu Ma, Xiaoyu Huang iD, Mingming Xu, Linlin Fu, Yong Zhang

Annals of Clinical and Translational Neurology · 2026

DOI: 10.1002/acn3.70261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2026. Verfasst von Tiancheng Luo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Myasthenia Gravis, Fibroblast Growth Factors, Receptors, Fc, Receptors, Cholinergic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Construction Project of High Level Hospital of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment.

Methods

We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG patients before and after EFG treatment. Serum levels of 92 inflammation‐related proteins were measured using Olink Target 96 proteomics in MG patients before and after EFG treatment. Validation was performed by enzyme‐linked immunosorbent assay in an expanded cohort and followed by in vitro experiments to evaluate the effects of novel biomarkers on peripheral blood mononuclear cells from MG patients.

Results

Following EFG treatment, patients showed significant reductions in MG Activities of Daily Living (MG‐ADL) scores and serum IgG levels, along with remodeling of immunocyte subset distribution. Olink proteomics analysis identified six differentially expressed inflammatory cytokines, among which fibroblast growth factor‐19 (FGF‐19) exhibited the most notable downregulation. Validation in an independent cohort demonstrated that serum FGF‐19 levels were elevated and positively correlated with disease severity in MG patients. Furthermore, in EFG responders, the expression level of FGF‐19 decreased after treatment. In vitro experiments demonstrated that FGF‐19 promotes B‐cell to plasma cell differentiation in MG patients.

Interpretation

EFG treatment can alleviate the clinical symptoms and decrease IgG levels in patients with MG. The downregulated expression following EFG treatment, along with the findings of in vitro experiments, indicates that FGF‐19 may not only act as a biomarker for the efficacy of EFG, but also play a role in promoting the differentiation of B cells into plasma cells, thereby offering a novel target for therapeutic interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisFibroblast Growth FactorsReceptors, FcReceptors, CholinergicHumansProteomicsMaleFemaleMiddle AgedBiomarkersAdultAutoantibodiesAged

Stichwörter der Autor:innen

FGF‐19Olinkbiomarkerefgartigimodmyasthenia gravis

Substanzen

BiomarkersFibroblast Growth FactorsReceptors, FcReceptors, CholinergicAutoantibodies

Autor:innen und Institutionen

  • Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
  • First Clinical Medical College, Xuzhou Medical University, Xuzhou, Jiangsu, China.
  • Central Laboratory, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
  • Department of Neurology, The Third People's Hospital Health Care Group of Cixi, Zhejiang, China.
  • Department of Pathogen Biology and Immunology, School of Basic Medical Sciences, Xuzhou Medical University, Xuzhou, Jiangsu, China.
  • Jiangsu Key Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, Jiangsu, China.

ORCID-Profile: Zhouao Zhang, Xiaoyu Huang

Förderung

  • Construction Project of High Level Hospital of Jiangsu Province

Zitieren

APA

Luo, T., Peng, D., Zhang, Z., Yang, M., Guo, X., Ma, T., Huang, X., Xu, M., Fu, L., & Zhang, Y. (2026). Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐ AChR Antibody‐Positive Myasthenia Gravis: FGF ‐19 as a Novel Biomarker. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70261

Vancouver

Luo T, Peng D, Zhang Z, Yang M, Guo X, Ma T, et al. Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐ AChR Antibody‐Positive Myasthenia Gravis: FGF ‐19 as a Novel Biomarker. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70261

BibTeX
@article{Luo2026,
  author = {Luo, Tiancheng and Peng, Deyou and Zhang, Zhouao and Yang, Mingjin and Guo, Xinyan and Ma, Tianyu and Huang, Xiaoyu and Xu, Mingming and Fu, Linlin and Zhang, Yong},
  title = {Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐ AChR Antibody‐Positive Myasthenia Gravis: FGF ‐19 as a Novel Biomarker},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  doi = {10.1002/acn3.70261}
}
Kostenlos starten →